This site is intended for health professionals only
Friday 31 October 2014
Share |

Positive results of new levodopa product for Parkinson's disease

INDUSTRY NEWS
ODM-101, a new levodopa product currently developed by Orion for the treatment of Parkinson's disease, has successfully completed Phase II Proof of Concept trial. The key results indicate that ODM-101 was more efficacious than the reference product Stalevo® in the treatment of advanced Parkinson's disease patients. The study included more than 100 patients in Europe.
 
Professor Claudia Trenkwalder, the Principal Investigator of the ODM-101 Proof of Concept study, comments:
 
"This phase II study demonstrated that ODM-101 has potential to be significantly more effective than Stalevo in the daily treatment of Parkinson's disease patients with response fluctuations. ODM-101 reduced time periods during the day when patients do not have adequate treatment response. These benefits were possible without an increase in troublesome involuntary movements (dyskinesia)."
Stalevo, a product of Orion's own pharmaceutical R&D, has been established by long-term clinical practice as a standard medication for advanced Parkinson's patients experiencing so-called end-of-dose wearing-off symptoms associated with levodopa therapy. Stalevo is an enhanced levodopa treatment containing three active substances in one tablet: levodopa and the enzyme inhibitors entacapone and carbidopa. Measured in overall sales of entacapone products in 2011, Orion is the world's leading manufacturer of Parkinson's drugs (IMS Health 2012)
 
About Parkinson's disease
Symptoms typical of Parkinson's disease, such as slowness of movements and tremor, are caused by the brain's inability to produce enough dopamine, a neurotransmitter important for the body's motor functions. Levodopa is the natural precursor of dopamine and thus the standard drug used in the treatment of Parkinson's symptoms. When used alone, most of levodopa is metabolised in the body before it reaches the brain. Enzyme inhibitors such as entacapone have thus been developed to enhance the effect of levodopa. An unmet medical need has however been identified for novel and even more effective levodopa treatments.
Typically when initiating the treatment with levodopa the patient's symptoms remain under control during the entire day. This period of good response is often referred to as "honeymoon". As the disease progresses, however, the action of levodopa gradually wears off and its improving effect becomes more irregular.
 
About Orion
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orion's net sales in 2011 amounted to EUR 918 million and the Company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine